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Abstract 
Objective: Computed tomography and chest radiographs provide the standard imaging for 
staging,  treatment,  and  surveillance  of  testicular  germ  cell  neoplasms. Positron  emission 
tomography has recently been utilized for staging, but is somewhat limited in its ability to 
provide anatomic localization. Fusion imaging combines the metabolic information provided 
by positron emission tomography with the anatomic precision of computed tomography. To 
the best of our knowledge, this represents the first study of the effectiveness using fusion 
imaging in evaluation of patients with testis cancer. 
Methods: A   p r o s p e c t i v e   s t u d y   o f   4 9   p a t i e n t s   p r e s e n t i n g   t o   W a l t e r   R e e d   A r m y   M e d i c al Center 
with testicular cancer from 2003 to 2009 was performed. Fusion imaging w a s   c o m p a r e d   w i t h  
conventional imaging, tumor markers, pathologic results, and clinical follow-up. 
Results: There were 14 true positives, 33 true negatives, 1 false positive, and 1 false negative. 
Sensitivity, specificity, positive predictive value, and negative predictive value were 93.3, 97.0, 
93.3, and 97.0% respectively. In 11 patient scenarios, fusion imaging differed from conventional 
imaging. Utility was found in superior lesion detection compared to helical computed to-
mography due to anatomical/functional image co-registration, detection of micrometastasis in 
lymph nodes (pathologic nodes < 1cm), surveillance for recurrence post-chemotherapy, 
differentiating fibrosis from active disease in nodes < 2.5cm, and acting as a quality assurance 
measure to computed tomography alone.  
Conclusions: In addition to demonstrating a sensitivity and specificity comparable or superior 
to conventional imaging, fusion imaging shows promise in providing additive data that may 
assist in clinical decision-making. 
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Introduction 
The incidence of testis cancer has been increasing 
a t   a n   a n n u a l   r a t e   o f   3 % ,   l e a d i n g   t o   a   d o u b l i n g   i n   c a s e s  
world-wide over the last 40 years. With the advent of 
improved  staging  and  treatment  there  has  been  a 
m a r k e d   d e c r e a s e   i n   m o r t a l i t y   o v e r   t h i s   t i m e ,   e s t i-
mated  at  4.5%  for  2009.1  In  recent  years,  positron 
e m i s s i o n   t o m o g r a p h y   ( P E T )   h a s   b e e n   u t i l i z e d   i n   c o n-
junctio n   w i t h   c o m p u t e d   t o m o g r a p h y   ( C T )   a n d   c h e s t  
r a d i o g r a p h s   ( C X R )   t o   s u r v e y   p a t i e n t s   f o r   m e t a s t a t i c   o r  
recurrent disease. While CT is the standard of care for 
locating the presence of lymphadenopathy or retro-
peritoneal masses, its false negative rates have been 
r e p o r t e d   t o   b e   a s   h i g h   a s   3 0 -59%.2,3 PET, with its abil-
ity to identify regions of increased metabolic activity, 
h a s   b e e n   s h o w n   t o   i m p r o v e   t h e   d e t e c t i o n   o f   t u m o r   a t  
initial staging and following chemotherapy.4-6 
 F i r s t   u s e d   c l i n i c a l l y   i n   2 0 0 1 ,   P E T / C T   s c a n n e r s  
combine both modalities into one device, generating Journal of Cancer 2010, 1 
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images  that  couple  the  metabolic sensitivity of PET 
w i t h   t h e   p r e c i s e   a n a t o m i c   d e t a i l   o f   C T . 7 Initial reports 
in non-small cell lung cancer, malignant lymphoma, 
and recurrent colorectal cancer suggest benefits in its 
use.8-10  Since  60-7 0 %   o f   p a t i e n t s   w i t h   S t a g e   I  
non-seminom a t o u s   g e r m   c e l l   t u m o r s   ( N S G C T )   a n d  
8 0 %   o f   S t a g e   I   s e m i n o m a   p a t i e n t s   d o   n o t   h a r b o r   o c c u l t  
m e t a s t a t i c   d i s e a s e   a n d ,   t h u s ,   d o   n o t   r e q u i r e   a d j u v a n t  
t h e r a p y ,   P E T / C T   c o u l d   r e d u c e   t h e   m o r b i d i t y   o f   t e s t i s  
cancer  treatment  if  it  could  identify  which  patients 
need adjuvant treatment.11,12 Furthermore, the utility 
o f   P E T   a l o n e   i n   t h e   e v a l u a t i o n   o f   p o s t -chemotherapy 
masses  suggests  another  a  role  for  PET/CT  in  the 
post-chemotherapy setting.13,14 T h e   g o a l   o f   t h i s   s t u d y  
i s   t o   p r o v i d e   a n   i n i t i a l   a s s e s s m e n t   o f   t h e   e f f i c a c y   o f  
fusion imaging with PET/CT in the management of 
testis cancer. 
Methods 
 A prospective analysis of 49 patients presenting 
to Walter Reed Army Medical Center (WRAMC) with 
an initial diagnosis of testicular cancer between 2003 
and  2009  was  conducted.  Patients  underwent  con-
ventional  imaging  evaluation  to  include  CT  abdo-
men/pelvis, CXR, as well as a full clinical evaluation 
to include medical history, physical examination, and 
serum  tumor  markers. Additionally, fusion imaging 
w i t h   P E T / C T   w a s   o b t a i n e d   o n   e a c h   p a t i e n t .   The 
WRAMC Clinical Investigation Committee and Hu-
man Use Committee approved the study. The patients 
t h e n   w e n t   o n   t o   r e c e i v e   c a r e   a s   d i c t a t e d   b y   N a t i o n a l  
Clinical  Cance r   N e t w o r k   ( N C C N )   g u i d e l i n e s .   T h e  
clinical utility of PET/CT was determined by pros-
pective outcomes.  
Information  regarding  radiotherapy,  retroperi-
toneal  lymph  node  dissection  (RPLND)  pathology, 
a n d / o r   c h e m o t h e r a p y   c o u r s e   w a s   o b t a i n e d   i n   a p p r o-
priate cases. All tissue specimens were reviewed at 
the  Armed  Forces  Institute  of  Pathology  with  sec-
ondary  review  by  a  genitourinary  pathologist  at 
WRAMC.  
 R o u t i n e   a x i a l   i m a g i n g ,   c o n s i s t i n g   o f   C T   o f   t h e  
abdomen and pelvis at 5mm intervals with oral and 
intravenous contrast administration was performed in 
48 patients (Lightspeed, GE, Fairfield, Connecticut). 
One patient had an initial non-contrast CT followed 
b y   a n   M R I   d u e   t o   a n   i n t r a v e n o u s   i o d i n a t e d   c o n t r a s t  
allergy. These images were interpreted by one staff 
radiologist with expertise in genitourinary imaging. 
L y m p h   n o d e s   l a r g e r   t h a n   1   c m   i n   d i a m e t e r   w e r e   c o n-
sidered pathologic. 
 A l l   P E T / C T   i m a g i n g   w a s   p e r f o r m e d   a t  
WRAMC (Biograph, Seimens, Munich, Germany) and 
evaluated by one of four attending nuclear medicine 
physicians. T h e   C T   i m a g e s   o b t a i n e d   w i t h   t h e   P E T   f o r  
fusion  imaging  were  without  contrast.  All  patients 
maintained a low carbohydrate diet for 12 hours prior 
to the examination and fingerstick glucose levels were 
determined  before  radiotracer  administration.  All 
p a t i e n t s   w e r e   e x a m i n e d   w i t h   a   P E T / C T   u p o n   i n i t i a l  
presentation.  Those  patients  that  underwent  more 
than one examination did so following treatment (i.e. 
chemotherapy or RPLND) as part of their follow-up if 
t h e r e   w a s   a   c l i n i c a l   s u s p i c i o n   o f   r e c u r r e n c e .   S U V val-
u e s   w e r e   c o m p a r e d   t o   b a c k g r o u n d   v a s c u l a t u r e   t o  
determine positivity with the final determination of 
positive uptake made by the attending nuclear medi-
cine physician blinded to adjunctive studies. 
 F o r   t h e   p u r p o s e s   o f   c a l c u l a t i n g   s e n s i t i v i t y ,   s p e-
cificit y   a n d   p r e d i c t i v e   v a l u e s ,   a   t r u e   p o s i t i v e   w a s   c o n-
f i r m e d   b y   h i s t o l o g y   o b t a i n e d   a t   R P L N D   ( n   =   3 )   o r  
e i t h e r   p o s i t i v e   s e r u m   m a r k e r s   o r   p o s i t i v e   C T   s i z e   c r i-
t e r i a   ( n   =   1 1 )   i n   t h o s e   p a t i e n t s   t h a t   d i d   n o t   u n d e r g o  
RPLND. A   t r u e   n e g a t i v e   w a s   d e f i n e d   b y   p a t h o l o g y  
when available (n = 15) or by negative follow-up ac-
companying a negative PET/CT (n = 18). False posi-
tives (n=1) and negatives (n=1) were defined either by 
pathologic findings or clinical follow up contrary to 
initial PET/CT results.  
Results 
Between 2003 and 2009, forty-nine patients were 
enrolled.  Median  patient  age  was  27  years  (range 
19-57  years).  Two  patients  were  Hispanic  and  the 
others were Caucasian. Median follow-up from initial 
presentation was 39 months (range 4 to 85 months). 
Clinical characteristics  of  the  patient  population  are 
detailed in Table 1. One patient classified as semino-
ma had a focus of teratoma and underwent RPLND as 
primary treatment. One patient classified as NSGCT 
h a d   p u r e   t e r a t o m a   s t a g e   I I I C ( S 1 )   h e   u n d e r w e n t   c h e-
motherapy and subsequent  RPLND. Tissue was ob-
tained from retroperitoneal lymph node dissections in 
28 patients.  
T h e r e   w e r e   1 4   t r u e   p o s i t i v e s ,   3 3   t r u e   n e g a t i v e s ,   1  
false positive, and 1 false negative. Sensitivity, speci-
ficity, positive predictive value and negative predic-
tive values are demonstrated in Table 2. The sole false 
positive case occurred in a patient who was initially 
d i a g n o s e d   w i t h   S t a g e   I s   N S G C T .  Due to elevated tu-
mor markers post operatively, the patient received 3 
cycles  BEP.  S u b s e q u e n t l y ,   h e   h a d   n o r m a l   C T   s c a n s  
and tumor markers. At his 12 month follow-up, sur-
veillance  imaging  revealed  a  right  1.3  cm  inguinal 
lymph  node,  ipsilateral  to  his  prior  orchiectomy. 
P E T / C T   a l s o   i n d i c a t e d   i n c r e a s e d   u p t a k e   i n   t h i s   a r e a .  
B i o p s y   o f   t h e   l y m p h   n o d e   d e m o n s t r a t e d   a   f o r e i g n  
body giant cell reaction. The sole false negative oc-Journal of Cancer 2010, 1 
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curred in a patient who initially elected to undergo 
R P L N D   d e s p i t e   n e g a t i v e   C T   a n d   P E T / C T   s c a n s .  Pa-
thologic  analysis  revealed  one  of  14  lymph  nodes 
containing embryonal  carcinoma,  confirming  a false 
negative  for  PET/CT.  Of  note,  four  months  later, 
s u r v e i l l a n c e   C T   n o t e d   a   1 . 4   c m   s u p r a h i l a r   n o d e   w i t h  
an  increased  uptake  on  PET/CT. The patient under-
went chemotherapy with full resolution of findings on 
subsequent  imaging  for  a  total  follow-up  of  42 
months.  
 
Table 1: Patient Clinical Features 
Orchiectomy Pathology  No. Pts 
  Seminoma  15 
  NSGCT  34 
Clinical Stage   
  Ia  22 
  Ib  1 
  Is  16 
  IIa  2 
  IIb  1 
  IIc  2 
  IIIa  2 
  IIIb  3 
  IIIc  0 
Treatment after orchiectomy   
  Observation  11 
  Radiation  2   
   
  Chemotherapy  8 
  Chemotherapy + RPLND  9 
  RPLND  16 
  RPLND + Chemotherapy  3 
 
Table 2: Sensitivity, specificity, predictive values, and con-
fidence intervals for PET/CT and CT alone 
  PET/CT  CT 
Sensitivity  93.3% (0.66-0.99)  60.0% (0.33-0.82) 
Specificity  97.0% (0.83-0.99)  82.3% (0.65-0.93) 
Positive Predictive 
Value 
 93.3% (0.66-0.99)  60.0% (0.33-0.82) 
Negative Predictive 
Value 
97.0% (0.83-0.99)  82.3% (0.65-0.93) 
 
 
 C T   a n d   P E T / C T   f i n d i n g s   m a t c h e d   i n   3 8   o f   4 9  
patients and where they differed, patient care had the 
potential  to be  altered  in  all 11 scenarios  (Table  3). 
After  being  offered  continued  surveillance  versus 
t r e a t m e n t ,   p a t i e n t s   1   a n d   2 ,   b o t h   o f   w h o m   h a d   p o s i-
t i v e   P E T / C T   a n d   n e g a t i v e   C T   f i n d i n g s ,   e l e c t e d   t o  
undergo chemotherapy. The CT scan for patient 1 had 
initially been read as negative. However, the PET/CT 
performed 14 days later identified a 2.6 cm node with 
i n c r e a s e d   r a d i o t r a c e r   u p t a k e   t h a t   w a s   v i s i b l e   o n   r e-
peat analysis of the initial CT. The post-chemotherapy 
PET/CT for both patients demonstrated cessation  of 
increased radiotracer uptake. Patient 3 had a positive 
C T   s c a n   w i t h   a   1 . 5   c m   n o d e   p a c k e t   a d j a c e n t   t o   t h e  
vena cava. T h e   P E T / C T   w a s   n e g a t i v e ,   a n d   t h e   p a t i e n t  
elected  for  surveillance.  S e r i a l   C T   a n d   P E T / C T   e x-
aminations over the ensuing 44 months have shown 
stable size and finally resolution of mass at last im-
aging.  Patient  4  had  a  negative  CT  and  positive 
P E T / C T   w i t h   a   1 . 8   c m   p a r a -a o r t i c   l y m p h   n o d e   ( s t a n-
d a r d   u p t a k e   v a l u e   ( S U V )   1 1 )   t h a t   c o u l d   n o t   b e   i d e n t i-
f i e d   o n   c o -registered  CT  images.  He  elected  to  un-
dergo chemotherapy and subsequently had normali-
zation of PET images in this area and no future re-
currence. P a t i e n t   5   h a d   a   p o s i t i v e   C T   a n d   C T / P E T   f o r  
a stage III NSGCT. After receiving chemotherapy the 
CT remained positive demonstrating a 1.5cm retrope-
r i t o n e a l   L N   a n d   t h e   P E T / C T   w a s   n e g a t i v e   f o r   m e t a-
bolic  activity.  Subsequent  RPLND  revealed  fibrosis 
only.  P a t i e n t   6   h a d   a   n e g a t i v e   C T   a n d   a   p o s i t i v e  
PET/CT obtained 18 days later. This scan revealed a 
1.5cm pre-aortic and a 2.5cm left psoas lymph node, 
SUV ’ s   f o r   b o t h   w e r e   1 6 .  Again, as in Patient 1, review 
o f   t h e   o r i g i n a l   C T   i n d i c a t e d   p r e s e n c e   o f   t h e s e   n o d e s .  
The patient received chemotherapy and had norma-
lization  of  imaging  subsequently.  Patient  7  had  a 
Stage  I  N S G C T   w i t h   n e g a t i v e   C T   a n d   p o s i t i v e  
PET/CT  indicating 1.2 and 0.9cm (SUV 3.6) lymph 
nodes on initial evaluation. He underwent observa-
t i o n   a n d   h i s   t u m o r   m a r k e r s   b e g a n   t o   r i s e   2   m o n t h s  
after  his  PET/CT. Repeat  CT  was  still  negative. He 
underwent chemotherapy with resolution of all find-
ings. Patient 8 h a d   S t a g e   I   N S G C T   a n d   i n i t i a l   C T   i n-
dicating multiple groups of equivocal lymph  nodes 
(each approximately 1cm) consistent with metastatic 
disease.  His  PET/CT  and  subsequent RPLND  were 
negative. P a t i e n t   9   h a d   s t a g e   I I I a   N S G C T   a n d   s u b s e-
quent  chemotherapy.  His  post-treatment  imaging 
revealed 2 nodes slightly greater than 1.0cm, and his 
PET/CT was negative. RPLND  revealed  fibrosis. Pa-
tient 10 initially presented with stage I NSGCT, his CT 
w a s   n e g a t i v e   b u t   C T / P E T   r e v e a l e d   a n   8 m m   p a-
ra-aortic lymph node (SUV 3.25)  (Figure  1).  Subse-
q u e n t   R P L N D   c o n f i r m e d   t h i s   t o   b e   p o s i t i v e   w i t h   a  
mixture of embryonal and teratomatous components. 
Patient 11 initially presented with Stage IIa NSGCT, 
h i s   C T   a n d   P E T / C T   a t   t h e   t i m e   o f   p r e s e n t a t i o n   c o n-
f i r m e d   t w o   p a r a -aortic lymp nodes 2.29 and 2.10cm 
(SUV 17). Chemotherapy was administered and sub-
sequent imaging noted no significant decrease in size 
o f   t h e s e   n o d e s   b u t   t h e y   w e r e   n o t   m e t a b o l i c a l l y   a c t i v e  
on  PET/CT.  Subsequent  RPLND  revealed  fibrosis. 
 Three patients in our series had evidence of  masses 
both on CT and PET/CT with teratoma on pathologic 
examination of the RPLND specimens. I t   s h o u l d   b e  Journal of Cancer 2010, 1 
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n o t e d   t h a t   i n   n o n e   o f   t h e s e   c a s e s   w a s   t h e   m a s s   m e t a-
bolically active, with maximum SUV being 2.2. Of the 
12 patients that underwent chemotherapy after a pos-
i t i v e   P E T / C T ,   a l l   h a d   a   r e p e a t   P E T / C T   f o l l o w i n g  
chemotherapy which was negative. 
 While not confirmed histologically, two patients 
w i t h   e l e v a t e d   t u m o r   m a r k e r s   d e m o n s t r a t e d   u p t a k e   o n  
P E T / C T   i n   n o d e s   < 1 c m .  After chemotherapy course, 
t h e   m e t a b o l i c   a c t i v i t y   i n   t h e s e   r e g i o n s   r e s o l v e d   a n d   n o  
further  recurrences  were  noted.  Additionally,  one 
patient  had  uptake  in  a  sub-centimeter  node  on 
P E T / C T   w h i c h   s u b s e q u e n t l y   w a s   c o n f i r m e d   t o   h a r b o r  
germ cell tumor. 
 
 
 
 
Figure 1. A (top image): CT image demonstrating an absence of lymph node enlargement in Patient 10.   B  (bottom image): 
Analogous PET/CT image with arrow indicating site of increased FDG metabolism. 
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Table 3: Study Subjects with Discordant CT and PET/CT Findings 
Patient  Primary Tumor 
Pathology and 
Stage 
CT Findings  PET/CT Findings (SUV)  Adjuvant Therapy  Follow-up 
1  NSGCT 
Stage IIb 
Negative†   Positive: 2.6cm node (16.7)  Chemotherapy  Normalization of PET/CT fol-
lowing chemotherapy 
2  NSGCT 
Stage Ia 
Negative  Positive (11.1)  Chemotherapy  Normalization of PET/CT fol-
lowing chemotherapy 
3  Seminoma 
Stage Ia 
Positive - 1.5 cm node 
packet 
Negative  N/A  44 months with NED 
4  NSGCT 
Stage Ia 
Negative  Positive: 1.8 cm node (11)  Chemotherapy  Normalization of PET/CT fol-
lowing chemotherapy 
5  NSGCT 
Stage IIIa 
Positive prior to and 
following chemothe-
rapy 
Positive prior to chemothe-
rapy (5.64), negative follow-
ing chemotherapy 
Chemotherapy followed 
by RPLND 
Fibrosis on pathologic examina-
tion of RPLND Specimen 
6  NSGCT 
Stage IIb 
Negative†  Positive: 1.5 cm preaortic (16) 
and 2.5 cm psoas nodes (16) 
Chemotherapy  Normalization of PET/CT fol-
lowing chemotherapy 
7  NSGCT Stage Ia  Negative  Positive: 1.2 & 0.9 cm nodes 
(3.6) 
Chemotherapy  Normalization of PET/CT fol-
lowing chemotherapy 
8  NSGCT Stage Ia  Positive – multiple 
1cm lymph nodes 
Negative  RPLND  No evidence of metastatic dis-
ease on pathologic examination 
of RPLND specimen 
9  NSGCT Stage 
IIIa 
Post-chemotherapy: 
Positive - 2 nodes 
>1.0cm 
Negative  Chemotherapy followed 
by RPLND 
Fibrosis on pathologic examina-
tion of RPLND Specimen 
10  NSGCT Stage Ia  Negative  Positive - 8mm para-aortic 
node (3.25) 
RPLND  Embryonal and teratomatous 
metastases on pathologic ex-
amination of RPLND Specimen 
11  NSGCT Stage IIa  Positive prior to and 
following chemothe-
rapy 
Positive prior to chemothe-
rapy (17); Negative follow-
ing chemotherapy. 
Chemotherapy followed 
by RPLND 
Fibrosis on pathologic examina-
tion of RPLND Specimen 
† Re-examination of CT scan in light of positive PET/CT Findings revealed pathologically enlarged lymph nodes. 
 
 
Discussion 
 Imaging plays a central role in the clinical stag-
ing,  surveillance,  and  post-treatment  follow  up  of 
testicular germ cell tumors. While CT and CXR have 
served as the standards for these evaluations, recent 
studies  have  demonstrated  the  utility  of  PET.4,5,13-16 
The biochemical foundation for PET is the increased 
glucose  metabolism  characteristic  of  malignant  tis-
s u e s ,   a s s a y e d   i n   P E T   v i a   f l u o r i n e -18 fluorodeoxyglu-
cose (FDG), a radiolabeled glucose analogue. Due  to 
its high cellular activity, testis cancer would be an 
ideal candidate for an imaging modality that incor-
porates this concept.  
Assessments of PET alone for the initial clinical 
staging of germ cell tumors have demonstrated sensi-
tivities  and  specificities  ranging  from  70-87%  and 
94-100%, respectively, while CT alone has produced 
sensitivities  of  37-100%  and  specificities  of 
58-100%.4,5,15-17  T h e   p e r f o r m a n c e   o f   P E T / C T   f u s i o n  
imaging in this pilot study was consistent with and in 
some  cases  superior  to  these  findings.  As  demon-
s t r a t e d   i n   t h e   1 1   i n d e x   p a t i e n t s   l i s t e d ,   P E T / C T   p r o-
vides additive information that may positively impact 
decision-making.  
In  the  post-chemotherapy  setting,  CT  cannot 
distinguish between viable tumor, fibrosis, and ma-
ture teratoma. P E T   h a s   b e e n   s h o w n   t o   i d e n t i f y   v i a b l e  
t u m o r   i n   r e s i d u a l   m a s s e s   f o r   b o t h   N S G C T   a n d   s e m i-
noma.13,14  In addition to distinguishing tumor from 
fibrosis or teratoma, Sugawara et al utilized  PET  ki-
netic  rate  constants  to  differentiate  mature  teratoma 
from fibrosis and necrosis.18 In our analysis, all tera-
tomatous  masses  were  metabolically  negative  on 
PET/CT. However, fusion imaging may still play a 
role in deciding between chemotherapy or surgery for 
the initial management of retroperitoneal masses by 
using metabolic activity as one additional data point. 
It may also have utility in surgical planning and con-
sideration of an additional cycle or salvage chemo-
therapy for patients with post-chemotherapy masses. 
When considering this application, one should con-
sider the findings of Cremerius et al, who described a 
h i g h   r a t e   o f   f a l s e   n e g a t i v e   P E T   s c a n s   w i t h i n   2   w e e k s  
following  chemotherapy,  a  finding  that  was  echoed 
by Hain and colleagues.6,19 Given that both PET alone 
and PET/CT use the same technology for detection of 
glucose metabolism, a minimum 2 week waiting pe-
riod  between  the  completion  of  chemotherapy  and 
performance of PET/CT is prudent.  
Another  application  to  consider  is  in  the  sur-
veillance of post-chemotherapy patients. In this anal-
ysis,  there  were  12  patients  that  underwent 
post-chemotherapy  PET/CT  following  a 
pre-chemotherapy positive PET/CT. All had negative 
PET/CT  evaluations  and  none  have  demonstrated Journal of Cancer 2010, 1 
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disease recurrence at a mean follow-up of 51 months. 
T h e s e   f i n d i n g s   s u p p o r t   t h e   r o l e   f o r   P E T / C T   i n   t h i s  
setting.  
Sugawara and colleagues expressed concern re-
garding the capacity   o f   P E T   t o   i d e n t i f y   r e s i d u a l   t u-
m o r s   s m a l l e r   t h a n   2   c m . 18 Similarly, it has been po-
sited that poor spatial resolution limits PET detection 
of disease in very small masses or lymph nodes.20 Our 
d a t a   o f f e r   s o m e   p r o m i s e   t h a t   P E T / C T ’ s  combination 
of the metabolic sensitivity of PET with the anatomic 
a c c u r a c y   o f   C T   m a y   p r o v i d e   e n h a n c e d   d e t e c t i o n   o f  
early  disease.  Specifically,  3  patients  had  positive 
PET/CT’s in the presence of negative CT alone. One 
h a d   p a t h o l o g i c   c o r r e l a t i o n   a n d   t h e   o ther two demon-
strated treatment response in these nodes. This sug-
gests an ability of PET/CT to detect disease before it 
would be identified by traditional methods.  
S i n c e   t h e   m a j o r i t y   o f   p a t i e n t s   w i t h   l o w   s t a g e  
seminoma  and  NSGCT  do  not  require  adjuvant 
treatment,  the  potential  of  PET/CT  to  identify  such 
patients offers a significant potential benefit. Patient 3, 
w h o   e l e c t e d   t o   u n d e r g o   s u r v e i l l a n c e   o f   a   1 . 5   c m   n o d e  
g r o u p   b a s e d   u p o n   a   n e g a t i v e   P E T / C T ,   h a s   e x p e-
rienced 44 months without either adjuvant therapy or 
disease recrudescence, providing an example of the 
p o t e n t i a l   o f   P E T / C T   t o   r e d u c e   t h e   n u m b e r s   o f   p a-
tients subjected to the morbidity of adjuvant therapy. 
I n   a d d i t i o n   t o   P a t i e n t   3 ,   P E T / C T   h a d   t h e   p o t e n t i a l   t o  
a b r o g a t e   a d d i t i o n a l   t h e r a p y   i n   4   o t h e r   i n s t a n ces  as 
noted above (Patients 5, 8 ,9, and 11) where nodes all < 
2.5cm demonstrated no metabolic activity and dem-
onstrated fibrosis on RPLND. 
Further potential benefits of PET/CT are in the 
comprehensive imaging of the chest. Controversy in 
this arena exist, but whole lung tomography can alter 
treatment decisions in approximately 3% of patients 
over chest x-ray alone.21 I t   c a n   a l s o   l i m i t   t h e   n e e d   t o  
do additive studies in the setting of a positive plain 
chest  x-ray.  F u r t h e r m o r e ,   P E T / C T   d o e s   n o t   u s e   I V  
c o n t r a s t   w h i c h   c a n   b e   c o m p l i c a t e d   b y   a l l e r g i c   a n d  
other  adverse  reactions.  Low-osmolality  ionic  and 
nonionic co n t r a s t   m e d i a   n o w   i n   c o m m o n   u s e   a r e   a s-
sociated  with  a  lower  overall  incidence  of  adverse 
effects than previous high osmolality agents. Allergic 
r e a c t i o n s   a r e   s t i l l   n o t e d   t o   o c c u r   i n   4 -8% of patients.22 
Serious contrast reactions including anaphylaxis are 
s e e n   i n   1   o r   2   p e r   1 , 0 0 0   e x a m i n a t i o n s   u s i n g   h i g h   o s-
molality contrast media and in 1 or 2 per 10,000 ex-
aminations using low-osmolality  contrast  media.22,23 
Contrast induced nephrotoxicity is probably related 
to the degree of pre-existing renal disease and hydra-
tion with reported rates between 2-7%, but its actual 
prevalence is unknown.22,23  
PET/CT can provide superior lesion detection 
compared to helical CT due to anatomical/functional 
image  registration,  thereby,  identifying  nodes  with 
micrometastases that are below the morphologic size 
c r i t e r i a   u s e d   f o r   n o d a l   detection  with  CT  alone. 
P E T / C T   m a y   a l s o   h i g h l i g h t   a n d   l e a d   t o   d e t e c t i o n   o f  
n o d e s   o t h e r w i s e   m i s s e d   o n   r o u t i n e   C T   d u e   t o   o v e r-
sight, obscuration by tortuous adjacent blood vessels, 
or overlying bowel.  
There  are  limitations  to  PET/CT.  Image  regis-
tration may be hampered by artifacts induced by pa-
tient  motion,  respiratory  motion,  or  by  metallic  im-
plants.  SUV  levels  obtained  by  manually  drawing 
r e g i o n s   o f   i n t e r e s t ,   b a s e d   u p o n   a   p e r c e n t a g e   o f   t h e  
maximum SUV, or an absolute v a l u e   o f   t h e   S U V   m a y  
lead to potential measurement errors. Areas with high 
physiologic  activity  such  as  the  liver  may  obscure 
small lesions. R e c e n t   c h e m o   o r   r a d i a t i o n   t h e r a p y   m a y  
limit the sensitivity of PET/CT. Oral and IV contrast 
for CT alone may lead to unwanted image artifacts on 
PET/CT. It   i s   i m p o r t a n t   t o   r e c o g n i z e   t h a t   f u s i o n   i m-
a g i n g   w i t h   P E T / C T   i s   n o t   a c c u r a t e   f o r   n o d e s   < 0 . 8   c m  
l a r g e l y   d u e   t o   p a r t i a l   v o l u m e   e f f e c t s . 24 Coupled with 
the risk of false positive PET/CT  due  metabolically 
a c t i v e   i n f e c t i o n   o r   i n f l a m m a t i o n ,   t h i s   i m a g i n g   m o d a l-
ity should not substitute for sound clinical judgment. 
However, complex clinical decisions benefit from ad-
d i t i v e   s o u r c e s   o f   d a t a .  P E T / C T   c a n   b e   a   u s e f u l   a d j u n c t  
for decision making b y   b e i n g   o n e   o f   t h o s e   s o u r c e s .  
Further multi-institutional investigation with a larger 
patient cohort is needed to further define its role.   
Conclusions 
 A c c u r a t e   s t a g i n g   o f   t e s t i c u l a r   g e r m   c e l l   t u m o r s   i s  
essential to guide patient counseling and selection of 
appropriate therapy. While CT and chest x-ray are the 
c u r r e n t   s t a n d a r d   o f   c a r e ,   P E T   h a s   r e c e n t l y   b e e n   u t i-
lized for both lesion detection and tumor staging. This 
is the first documented evaluation of fusion imaging 
w i t h   P E T / C T   i n   t e s t i s   c a n c e r   w h i c h   s u g gests  that 
combining these two imaging modalities may afford 
superior detection and localization of tumor as com-
pared  with  either  one  alone.  Identification  of 
sub-centimeter  nodal  micro-metastases  at  initial 
staging,  surveillance  for  recurrence,  distinguishing 
active tumor from teratoma or fibrosis, and appropri-
a t e   t r i a g e   o f   p a t i e n t s   f o r   p r i m a r y   o r   s e c o n d a r y   t h e r a p y  
are promising benchmarks for future investigations of 
PET/CT in the evaluation of testis cancer.  
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